title: Treatment of endstage heart disease with mechanical circulatory assistance.
abstract: A great number of patients suffer and die from the sequelae of acute and chronic heart failure each year. Although advances in medical and surgical therapy have benefited many of these patients, the majority suffer from disease refractory to any definitive therapy. For these patients, cardiac transplantation is the only remaining hope. Unfortunately, because of the increasing demand for donor organs in the face of a fixed and limited supply, this option is only available to a small percentage of these patients. Even in patients accepted for transplantation, a significant waiting list mortality has been observed. A variety of ventricular assist devices (VAD) have been developed since the first successful case of mechanical cardiac assistance over 30 years ago. These devices differ in basic mechanical function, method of insertion, and degree of implantability, and thus have different indications and potential applications. While the intra-aortic balloon pump and centrifugal pumps are effective short-term support modalities, extracorporeal and implantable pulsatile devices have been used successfully for long-term support of patients with reversible and non-reversible cardiac failure. These pumps have most commonly been utilized as bridges to transplantation, but increasing clinical experience has supported the notion of long-term mechanical assistance as a definitive therapy for endstage heart disease. While complications, particularly infection and thromboembolism, pose significant challenges and long-term device reliability remains to be fully determined, available implantable devices seem capable of providing effective long-term support. As data is obtained from currently ongoing trials comparing VAD support to medical therapy for endstage heart failure, ethical and economic issues will assume increasing importance.
authors.affiliation: Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, N.Y. 10032, USA.
authors.forename: M
authors.initials: M
authors.lastname: Argenziano
authors.forename: J J
authors.initials: JJ
authors.lastname: DeRose
authors.forename: M C
authors.initials: MC
authors.lastname: Oz
authors.forename: E A
authors.initials: EA
authors.lastname: Rose
mesh_terms: D001243:Assisted Circulation / Q000009:adverse effects / Q000191:economics; D002303:Cardiac Output, Low / Q000191:economics / Q000628:therapy*; D003363:Cost Control; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D007239:Infections / Q000209:etiology; D013923:Thromboembolism / Q000209:etiology; D018497:Ventricular Dysfunction, Right / Q000209:etiology